Non-dilated left ventricular cardiomyopathy in patients with chronic Chagas disease and heart failure with reduced left ventricular ejection fraction
ESC Heart Failure · 2026
DOI: 10.1093/eschf/xvag020 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESC Heart Failure, 2026. Verfasst von Reinaldo B Bestetti und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Ribeirão Preto, Ribeirão Preto city 14096-900, Brazil. Hauptthemen laut MEDLINE: Stroke Volume, Chagas Cardiomyopathy, Heart Failure, Ventricular Function, Left. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Ribeirão Preto.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Introduction
The aim of this investigation was to establish the clinical characteristics and outcomes of patients with non-dilated left ventricular cardiomyopathy (NDLVC) secondary to chronic Chagas disease (CChD).
Methods
All patients with CChD followed at our institution from January 2000 to January 2010 were included. Patients with a left ventricular ejection fraction (LVEF) <50%, a left ventricular diastolic diameter (LVDD) <55 mm, and segmental wall motion abnormalities (SWMA) on echocardiography were diagnosed with NDLVC secondary to CChD. The remaining patients had dilated cardiomyopathy (DCM) secondary to CChD.
Results
Of the 215 patients, 21 (10%) had NDLVC. In this group, the mean age was 62 ± 9 years, 12 (57%) were male, the median daily dose of metoprolol was 100 (62, 5, 125) mg, the LVDD was 51 ± 29 mm, and the LVEF was 39 ± 6.4%. SWMA were found in 12 (57%) patients. Mean follow-up 50.8 ± 3.8 months, during which 9 (43%) patients died. In a Cox regression model, Beta-blocker therapy was the only independent predictor of all-cause mortality for patients with NDLVC (hazard ratio = 0.16, 95% CI 0.04-0.68; P = .01) Over a 60-month follow-up, Kaplan-Meier survival estimates at 12, 24, 36, 48, and 60 months, were 71%, 71%, 59%, 59%, and 59%, respectively, in patients with NDLVC, and 77%, 61%, 49%, 38%, and 30%, respectively, in those with DCM due to CChD (P = .04).
Conclusions
Non-dilated left ventricular cardiomyopathy affects one in 10 patients with CHF due to CChD, and the 5-year survival rate is 59%.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, University of Ribeirão Preto, Ribeirão Preto city 14096-900, Brazil.
- Division of Postgraduation, São José do Rio Preto Medical School, São José do Rio Preto city, Brazil.
- Fundação Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto city, Brazil.
- Department of Cardiology and Cardiovascular Surgery, São José do Rio Preto Medical School, São José do Rio Preto city, Brazil.
ORCID-Profile: Reinaldo B Bestetti, Ana Paula Otaviano, Marcelo A Nakazone
Förderung
- University of Ribeirão Preto
Zitieren
APA
Bestetti, R. B., Cardinalli-Neto, A., Otaviano, A. P., Machado, M. N., Pavarino, P. R., & Nakazone, M. A. (2026). Non-dilated left ventricular cardiomyopathy in patients with chronic Chagas disease and heart failure with reduced left ventricular ejection fraction. ESC Heart Failure. https://doi.org/10.1093/eschf/xvag020
Vancouver
Bestetti RB, Cardinalli-Neto A, Otaviano AP, Machado MN, Pavarino PR, Nakazone MA. Non-dilated left ventricular cardiomyopathy in patients with chronic Chagas disease and heart failure with reduced left ventricular ejection fraction. ESC Heart Failure. 2026. doi:10.1093/eschf/xvag020
BibTeX
@article{Bestetti2026,
author = {Bestetti, Reinaldo B and Cardinalli-Neto, Augusto and Otaviano, Ana Paula and Machado, Mauricio N and Pavarino, Paulo R and Nakazone, Marcelo A},
title = {Non-dilated left ventricular cardiomyopathy in patients with chronic Chagas disease and heart failure with reduced left ventricular ejection fraction},
journal = {ESC Heart Failure},
year = {2026},
doi = {10.1093/eschf/xvag020}
}
EUVIMED